Roquefort Therapeutics plc (LON: ROQ)

Roquefort Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.6	0.54	2.32	0.9
Cash & Short-Term Investments	0.6	0.54	2.32	0.9
Cash Growth	-56.81%	-76.87%	158.19%	-
Accounts Receivable	0.09	-	-	0.02
Other Receivables	-	0.11	0.05	2.14
Receivables	0.09	0.11	0.05	2.15
Prepaid Expenses	-	0.05	0.06	0.03
Total Current Assets	0.68	0.69	2.42	3.08
Property, Plant & Equipment	0.05	0.05	-	-
Goodwill	-	0.28	0.28	0.28
Other Intangible Assets	5.34	5.06	5.06	1.2
Total Assets	6.07	6.09	7.77	4.56
Accounts Payable	0.14	0.14	0.07	0.04
Accrued Expenses	0.12	0.16	0.21	0.15
Total Current Liabilities	0.86	0.31	0.28	0.2
Long-Term Deferred Tax Liabilities	0.28	0.28	0.28	0.28
Total Liabilities	1.14	0.59	0.56	0.48
Common Stock	1.29	1.29	1.29	0.72
Additional Paid-In Capital	4.4	4.4	4.4	3.46
Retained Earnings	-4.87	-4.29	-2.55	-0.91
Comprehensive Income & Other	4.11	4.1	4.06	0.82
Shareholders' Equity	4.93	5.5	7.21	4.08
Total Liabilities & Equity	6.07	6.09	7.77	4.56
Net Cash (Debt)	-0.01	0.54	2.32	0.9
Net Cash Growth	-	-76.87%	158.19%	-
Net Cash Per Share	-0.00	0.00	0.02	0.04
Filing Date Shares Outstanding	129.15	129.15	129.15	71.9
Total Common Shares Outstanding	129.15	129.15	129.15	71.9
Working Capital	-0.18	0.39	2.15	2.88
Book Value Per Share	0.04	0.04	0.06	0.06
Tangible Book Value	-0.41	0.16	1.86	2.6
Tangible Book Value Per Share	-0.00	0.00	0.01	0.04
Machinery	-	0.05	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.